TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26549533

Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 2305

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 2305

Group type: EXPERIMENTAL
Intervention: 8-predictor model
Number of subjects: 2305

Group type: COMPARATOR
Intervention: 14-predictor Seattle model
Number of subjects: 2305
Study: 24672940

Group type: EXPERIMENTAL
Intervention: Chinese medical decoction
Number of subjects: 81

Group type: COMPARATOR
Intervention: Ganciclovir and pidotimod
Number of subjects: 81
Study: 22037127

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation (VNS)
Number of subjects: 13
Study: 19911325

Group type: EXPERIMENTAL
Intervention: Structured telephone aftercare
Number of subjects: 527

Group type: EXPERIMENTAL
Intervention: Non‐directive telephone aftercare
Number of subjects: 527

Group type: COMPARATOR
Intervention: No aftercare (control group)
Number of subjects: 527
Study: 17326083

Group type: EXPERIMENTAL
Intervention: SCA2 patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MSA‐C patients
Number of subjects: 15

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: SCA2 and MSA‐C patients
Number of subjects: 15
Study: 15147247

Group type: EXPERIMENTAL
Intervention: Frovatriptan 2.5 mg
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75

Group type: COMPARATOR
Intervention: Frovatriptan 2.5 mg and Placebo
Number of subjects: 75
Study: 12352234

Group type: EXPERIMENTAL
Intervention: Metronidazole 400 mg three times daily for seven days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 9839847

Group type: COMPARATOR
Intervention: C: 25 g creatine monohydrate/day, 5 days
Number of subjects: 12

Group type: COMPARATOR
Intervention: CC: 25 g creatine monohydrate/day, 5 days plus 5 g/h during exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: P: Placebo
Number of subjects: 12
Study: 8301790

Group type: EXPERIMENTAL
Intervention: 22-mg nicotine patch therapy with intensive group counseling for 8 weeks (Study 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 22-mg nicotine patch therapy for 4 weeks followed by 11-mg nicotine patch therapy for 2 weeks with brief individual counseling (Study 2)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 22-mg nicotine patch therapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 200
Study: 2494246

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant tissue‐type plasminogen activator (rt‐PA)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Intravenous streptokinase
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Sustained reperfusion
Number of subjects: 290

Group type: COMPARATOR
Intervention: Nonsustained reperfusion
Number of subjects: 290
Study: 31496425

Group type: EXPERIMENTAL
Intervention: 90Y‐IT consolidation
Number of subjects: 75

Group type: COMPARATOR
Intervention: Rituximab maintenance
Number of subjects: 75
Study: 28659181

Group type: EXPERIMENTAL
Intervention: Cisplatin and ifosfamide with or without paclitaxel
Number of subjects: 45
Study: 25981847

Group type: EXPERIMENTAL
Intervention: High proactive coping (physicians in the highest quartile)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: High MSTAT (physicians in the highest quartile)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: High Need for Cognition (physicians in the highest quartile)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Low anxiety (physicians in the lowest quartile)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: High proactive coping (adjusted odds ratio)
Number of subjects: 1502

Group type: EXPERIMENTAL
Intervention: Low anxiety (adjusted odds ratio)
Number of subjects: 1502
Study: 23695806

Group type: EXPERIMENTAL
Intervention: Tc-99m-HDP-SPECT/CT analysis
Number of subjects: 100
Study: 21955830

Group type: EXPERIMENTAL
Intervention: Continuous extrapleural block
Number of subjects: 48

Group type: COMPARATOR
Intervention: Continuous epidural block
Number of subjects: 48
Study: 19921357

Group type: EXPERIMENTAL
Intervention: Flurbiprofen 1 mg kg(‐1) before surgery
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo (lipid emulsion 0.1 ml kg(‐1)) before surgery
Number of subjects: 44
Study: 17010568

Group type: EXPERIMENTAL
Intervention: Cholestyramine (CSM) therapy for 2 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cholestyramine (CSM) therapy reinstated for 2 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo therapy for 2 weeks
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cholestyramine (CSM) therapy after placebo
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exposure to WDBs
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Measurements of MMP9, leptin, VEGF
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Measurements of MMP9, leptin, VEGF at Time Point 5
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Participants with abnormal levels of MMP9, leptin, VEGF, pulmonary function at Time Point 5
Number of subjects: 26
Study: 15516022

Group type: COMPARATOR
Intervention: Single-dose CF101 (1, 5, or 10 mg)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Multiple-dose CF101 (2, 3, 4, or 5 mg, 12-hourly for 7 days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Single-dose CF101 (5 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: First multiple-dose CF101 (5 mg)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: After 7 days of multiple dosing
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Heart rate increase after CF101
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Leucocytosis after CF101 (5 and 10 mg)
Number of subjects: 43
Study: 15689068

Group type: EXPERIMENTAL
Intervention: Artesunate (3.3 mg/kg on day 1, followed by 1.65 mg/kg for the next four days, total dose = 600 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Artesunate followed by primaquine (15 mg for 14 days)
Number of subjects: 42
Study: 10615228

Group type: EXPERIMENTAL
Intervention: Doctor-patient discussions about RCTs
Number of subjects: 82
Study: 7785999

Group type: EXPERIMENTAL
Intervention: Cefepime (n = 43)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefotaxime (n = 47)
Number of subjects: 90
Study: 2195054

Group type: EXPERIMENTAL
Intervention: Fenfluramine
Number of subjects: 20
Study: 272945

Group type: EXPERIMENTAL
Intervention: L‐asparaginase 1,000 mu/kg iv q.d. x 10, vincristine 2.0 mg/m2 iv q.w. x 4 and prednisone 40 mg/m2 p.o.q.d. x 28 days
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Various combinations of cytosine arabinoside, cyclophosphamide, vincristine, prednisone, BCNU or CCNU
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: BCNU or CCNU
Number of subjects: 227
Study: 27909178

Group type: EXPERIMENTAL
Intervention: Routine inquiry about violence victimization and empowering strategies
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Routine inquiry about violence victimization
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Control group (questionnaires about victimization after the visit)
Number of subjects: 1051

Group type: EXPERIMENTAL
Intervention: Victimized young women in the intervention group
Number of subjects: 1051
Study: 31181088

Group type: EXPERIMENTAL
Intervention: Active education policy promoting inclusion since 2005
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Schools in Afghanistan
Number of subjects: 0
Study: 27730325

Group type: EXPERIMENTAL
Intervention: Conventional dexamethasone nasal spray
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Device using pressure and vibration to distribute steroid aerosol endonasally
Number of subjects: 0
Study: 25109276

Group type: EXPERIMENTAL
Intervention: Multipoint left ventricular pacing (MPP)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional left ventricular pacing (CONV)
Number of subjects: 44
Study: 25092886

Group type: EXPERIMENTAL
Intervention: HRM diet (300 g/day lean red meat)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: HRM+HAMSB diet (HRM with 40 g/day butyrylated high amylose maize starch)
Number of subjects: 23
Study: 22561907

Group type: EXPERIMENTAL
Intervention: ERSPC risk calculator
Number of subjects: 495

Group type: COMPARATOR
Intervention: PCPT model
Number of subjects: 495

Group type: COMPARATOR
Intervention: PSA threshold of 4 ng ml(‐1)
Number of subjects: 495
Study: 19486621

Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 739

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 739
Study: 17692112

Group type: EXPERIMENTAL
Intervention: Oral anticoagulant therapy (OAT)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: No antithrombotic therapy (AT)
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: OAT prescription in 2004
Number of subjects: 701
Study: 15351853

Group type: EXPERIMENTAL
Intervention: Topically applied aprotinin (1.0 x 10(6) KIU)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vehicle solution (control group)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (6.0 x 10(6) KIU) systemically for both groups
Number of subjects: 44
Study: 11110645

Group type: EXPERIMENTAL
Intervention: Intranasal (inl) immunization with monovalent, live attenuated, cold‐adapted recombinant (CR) or inactivated influenza virus (MIV) vaccine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Combined inl (CR or MIV) and im vaccine
Number of subjects: 12

Group type: COMPARATOR
Intervention: Intramuscular (im) immunization with MIV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9701860

Group type: EXPERIMENTAL
Intervention: Guidelines for assuring adherence (individual)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Guidelines for assuring adherence (family support)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Medication information procedure
Number of subjects: 39
Study: 8023663

Group type: EXPERIMENTAL
Intervention: Midazolam 75 micrograms.kg-1 followed by continuous infusion of propofol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Propofol 1.5 mg.kg-1 bolus followed by infusion
Number of subjects: 80
Study: 2688396

Group type: EXPERIMENTAL
Intervention: Mashed bean flakes meal
Number of subjects: 6

Group type: COMPARATOR
Intervention: Potato flakes meal
Number of subjects: 6
Study: 31003677

Group type: EXPERIMENTAL
Intervention: 5% grape seed extract ointment
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: 2.5% grape seed extract ointment
Number of subjects: 129

Group type: COMPARATOR
Intervention: Petrolatum
Number of subjects: 129
Study: 28550709

Group type: EXPERIMENTAL
Intervention: High heart rate in patients with abnormal renal function
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: High heart rate in patients with normal renal function
Number of subjects: 3923

Group type: EXPERIMENTAL
Intervention: Each 10 bpm increase of heart rate
Number of subjects: 3923
Study: 24983681

Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction at 38 weeks of gestation
Number of subjects: 31169

Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction at 39 weeks of gestation
Number of subjects: 31169

Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction at 40 weeks of gestation
Number of subjects: 31169

Group type: EXPERIMENTAL
Intervention: Nonmedically indicated induction
Number of subjects: 31169

Group type: COMPARATOR
Intervention: Expectant treatment
Number of subjects: 31169
Study: 23413265

Group type: EXPERIMENTAL
Intervention: Medical masks
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: Targeted use of N95 respirators
Number of subjects: 1669

Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Continuous use of N95 respirators
Number of subjects: 1669
Study: 21545991

Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 420

Group type: COMPARATOR
Intervention: Iopromide
Number of subjects: 420
Study: 19262754

Group type: EXPERIMENTAL
Intervention: FMP1/AS02 (50 microg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Rabipur(R) rabies vaccine
Number of subjects: 400
Study: 16516844

Group type: EXPERIMENTAL
Intervention: Vertical keyboard
Number of subjects: 9
Study: 15031276

Group type: EXPERIMENTAL
Intervention: Dietary intervention to promote eating five or more portions of fruit and vegetables a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Initial intervention appointment discussions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Final appointment discussions after 6 months
Number of subjects: 40
Study: 11348956

Group type: EXPERIMENTAL
Intervention: IV diltiazem (n = 167)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo (n = 163)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: IV diltiazem
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 10436538

Group type: EXPERIMENTAL
Intervention: Rapid dipstick tests for nitrite and leucocyte esterase
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Rapid dipstick tests for nitrite and leucocyte esterase in children less than one year old
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Leucocyte esterase strip test
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Leucocyte esterase strip test in children less than one year old
Number of subjects: 375
Study: 8061850

Group type: EXPERIMENTAL
Intervention: Spirapril
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Spiraprilat
Number of subjects: 0
Study: 2468896

Group type: EXPERIMENTAL
Intervention: Nifedipine, 10 mg p.o.
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 31567997

Group type: EXPERIMENTAL
Intervention: Pressure-Controlled Ventilation (PCV)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Volume-Controlled Ventilation (VCV)
Number of subjects: 86
Study: 28987445

Group type: EXPERIMENTAL
Intervention: Co-administration of IIV4 and PPV23
Number of subjects: 334

Group type: COMPARATOR
Intervention: Separate administration of IIV4 and PPV23
Number of subjects: 334
Study: 25224961

Group type: EXPERIMENTAL
Intervention: Minimal Access Spine Technologies (MAST) approach
Number of subjects: 61

Group type: COMPARATOR
Intervention: Conventional Open Approach (COA)
Number of subjects: 61
Study: 22677718

Group type: EXPERIMENTAL
Intervention: Pyridostigmine (60 mg three times a day, increasing to maximum tolerated dose or 120 mg three times a day for 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 21292873

Group type: EXPERIMENTAL
Intervention: Montanide ISA 720
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Montanide ISA 51
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: N, R, and C peptides
Number of subjects: 40
Study: 17541211

Group type: EXPERIMENTAL
Intervention: ACEI temocapril (T) 2 mg/day
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ARB candesartan (C) 4 mg/day
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combination therapy (T+C)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combination therapy (C+T)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Nifedipine-CR (N) 20 mg/day
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ACEI temocapril (T)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ARB candesartan (C)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: ACEI and/or ARB
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Combination of low doses of ACEI and ARB
Number of subjects: 164
Study: 15704503

Group type: EXPERIMENTAL
Intervention: Intensive exercise programme and back school education
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Home exercise programme and back school education
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no education or exercise)
Number of subjects: 60
Study: 11932280

Group type: EXPERIMENTAL
Intervention: Estrogen (E) alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Testosterone (T) alone
Number of subjects: 59

Group type: COMPARATOR
Intervention: Both E and T withdrawn
Number of subjects: 59
Study: 9459322

Group type: EXPERIMENTAL
Intervention: Factor V Leiden positive subjects
Number of subjects: 165

Group type: COMPARATOR
Intervention: Factor V Leiden negative subjects
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Factor V Leiden positive and negative subjects
Number of subjects: 165
Study: 7615407

Group type: EXPERIMENTAL
Intervention: Intermittent mandatory ventilation (IMV) at 10 breaths per minute
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Intermittent mandatory ventilation (IMV) at 20 breaths per minute
Number of subjects: 7

Group type: COMPARATOR
Intervention: Intermittent mandatory ventilation (IMV) rates of 10 and 20 breaths per minute
Number of subjects: 7
Study: 2550046

Group type: EXPERIMENTAL
Intervention: Isoprenaline (ISO) infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Isoprenaline (ISO) bolus injections
Number of subjects: 0
Study: 779587

Group type: EXPERIMENTAL
Intervention: Clonidine 0.225 mg daily (mean dosage varied from 0.225 to 0.900 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Practolol 200 mg daily (mean dosage varied from 200 to 600 mg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chlorothiazide 25 mg added to clonidine in 15 cases
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Chlorothiazide 25 mg added to practolol in 18 cases
Number of subjects: 42
Study: 30088285

Group type: EXPERIMENTAL
Intervention: Parents as Teachers (PAT) program
Number of subjects: 251
Study: 26599038

Group type: EXPERIMENTAL
Intervention: LcS‐fermented milk
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 72
Study: 25517820

Group type: EXPERIMENTAL
Intervention: RMP formulation E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: INH formulations A, B, C, and D
Number of subjects: 0

Group type: COMPARATOR
Intervention: RMP formulations A, B, C, and D
Number of subjects: 0

Group type: COMPARATOR
Intervention: INH formulation E
Number of subjects: 0
Study: 22821273

Group type: EXPERIMENTAL
Intervention: Cardiac troponin (cTn)
Number of subjects: 2121

Group type: COMPARATOR
Intervention: CK-MB mass
Number of subjects: 2121

Group type: COMPARATOR
Intervention: CK-based definition of MI
Number of subjects: 2121
Study: 20230611

Group type: EXPERIMENTAL
Intervention: Medication review and cognitive behaviour therapy by community pharmacists
Number of subjects: 342

Group type: COMPARATOR
Intervention: Usual care according to the Dutch Pharmacy Standard
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Treatment
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Medication Adherence Report Scale Questionnaire
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Follow-up at 12 months
Number of subjects: 342
Study: 17900325

Group type: EXPERIMENTAL
Intervention: Ultraflex stent
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Polyflex stent
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Niti-S stent
Number of subjects: 125

Group type: COMPARATOR
Intervention: All stents
Number of subjects: 125
Study: 15799725

Group type: EXPERIMENTAL
Intervention: Dorzolamide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 12749486

Group type: EXPERIMENTAL
Intervention: Permethrin-treated bed nets (ITNs)
Number of subjects: 780
Study: 11092511

Group type: EXPERIMENTAL
Intervention: Very-low-fat diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Background diet high in carbohydrate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Background diet high in monounsaturated fatty acids (MUFAs)
Number of subjects: 0
Study: 8819441

Group type: EXPERIMENTAL
Intervention: Cervex brush
Number of subjects: 15882

Group type: COMPARATOR
Intervention: Aylesbury spatula
Number of subjects: 15882
Study: 1578912

Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation (BMT)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Autologous Bone Marrow Transplantation (ABMT)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Intensive Consolidation Chemotherapy (ICC)
Number of subjects: 223
Study: 3935869

Group type: EXPERIMENTAL
Intervention: Buserelin (3 X 400 micrograms intranasally)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Buserelin (2 X 1 mg subcutaneously after parenteral treatment with 3 mg per day in the first week)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Buserelin (3 X 400 micrograms intranasally) + Tamoxifen (2 X 20 mg)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Buserelin (3 X 400 micrograms intranasally) + Megestrol acetate (4 X 45 mg)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Buserelin alone
Number of subjects: 31
Study: 31414562

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg
Number of subjects: 295
Study: 29560543

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at high frequency (400 bpm)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at medium frequency (200 bpm)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Autogenic drainage (AD)
Number of subjects: 4
Study: 27080498

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² on day 1 and day 6 during the first two courses of chemotherapy) plus chemotherapy (lymphome malin B [LMB])
Number of subjects: 260

Group type: COMPARATOR
Intervention: Chemotherapy alone (no rituximab)
Number of subjects: 260
Study: 24675955

Group type: EXPERIMENTAL
Intervention: Carolina Abecedarian Project (ABC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study: 21696703

Group type: EXPERIMENTAL
Intervention: Discomfort evaluation system
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Continuum evaluation system
Number of subjects: 72

Group type: COMPARATOR
Intervention: Comfort evaluation system
Number of subjects: 72
Study: 21199120

Group type: EXPERIMENTAL
Intervention: Pressure Control Ventilation (PCV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Volume Control Ventilation (VCV)
Number of subjects: 40
Study: 17611322

Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (Group A and B: 16-25 mg/10s; Group C and D: 6-7 mg/10s)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Propofol with midazolam (Group A and B: 30 seconds to 1 minute interval; Group C and D: 3 to 5 minute interval)
Number of subjects: 400